AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...
AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...
AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...
AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...
AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...
AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...
AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...
AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...
AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...
AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...
AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...
AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...
AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...
AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...
AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...
AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...
